ArticleBMC complementary medicine and therapies2026
In vitro assessment of the impact of astragalus, pineapple stem and bergamot extracts on human fecal bacteria.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBotanical extracts are increasingly incorporated into functional foods and dietary supplements due to their purported health benefits; however, their impact on the healthy adult gut microbiota remains insufficiently characterized. This study aimed to assess the microbiota-modulating potential of three commercially relevant botanicals (Astragalus membranaceus root extract, pineapple stem extract, and bergamot extract) in both native and digested forms, simulating gastrointestinal passage via the standardized INFOGEST protocol.
methodsAntimicrobial activity was first evaluated in monocultures of nine gut-associated bacterial strains representative of the healthy adult intestinal microbiota, including Lactobacillus acidophilus LA14, Lacticaseibacillus paracasei DG, Hafnia alvei HA4597, Bifidobacterium longum BB536, and B. animalis subsp. lactis BL-04. Botanicals were tested up to a supraphysiological concentration (100 mg/mL, worst-case exposure). Subsequently, each extract (native and digested) was incubated for 48 h under anaerobic conditions with a complex bacterial consortium derived from multiple fecal aliquots obtained from a single healthy adult donor. Microbial composition was assessed using 16 S rRNA gene profiling. α-diversity (Shannon index) and β-diversity (Bray-Curtis distances) were computed, and differential abundance was analyzed.
resultsIn monoculture, botanical extracts exhibited minimal and strain-specific antimicrobial activity at 100 mg/mL, with inhibition observed primarily for Akkermansia muciniphila, Bacteroides fragilis, and Collinsella aerofaciens. In the fecal consortium model, none of the botanical treatments, regardless of digestion status, produced significant alterations in α- or β-diversity. Modest taxonomic changes were detected, including a reproducible decrease in Collinsella spp. following treatment with digested Astragalus extract. Notably, core beneficial taxa such as Faecalibacterium prausnitzii and A. muciniphila remained unaffected.
conclusionsAt physiologically relevant concentrations, Astragalus membranaceus, pineapple stem, and bergamot extracts, in both native and digested forms, do not induce disruptive effects on the structure of the human gut microbial community, supporting their microbiome compatibility under the conditions tested.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.